Original Paper | 09-October-2019
Daratumumab is an antibody currently used in the treatment of patients with refractory multiple myeloma. Blood samples from patients being treated with daratumumab may show panreactivity during pre-transfusion testing. To facilitate the provision of blood components for such patients, it is recommended that a baseline phenotype or genotype be established prior to starting treatment with daratumumab. If patient red blood cells (RBCs) require phenotyping after the start of daratumumab treatment
Nicholas J. Lintel,
Debra K. Brown,
Diane T. Schafer,
Farai M. Tsimba-Chitsva,
Scott A. Koepsell,
Sara M. Shunkwiler
Immunohematology, Volume 33 , ISSUE 1, 22–26
Article | 17-February-2021
Multiple myeloma (MM) is a neoplastic disorder of the bone marrow involving the proliferation of plasma cells. High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is the mainstay of treatment for newly diagnosed, transplant-eligible patients with MM. However, for patients who are not eligible for ASCT or those who do not opt for ASCT, novel agents in the treatment of MM are being developed. Among these drugs, daratumumab (DARA), an IgG1к human monoclonal antibody that
Immunohematology, Volume 36 , ISSUE 4, 157–165
Report | 09-October-2019
Daratumumab (DARA), a drug used to treat patients with multiple myeloma, causes interference in pre-transfusion testing. Samples from patients receiving DARA exhibit panreactivity in antibody detection and identification tests with red blood cells (RBCs). Many hospitals are sending these samples to reference laboratories. Dithiothreitol (DTT), a sulfhydryl chemical treatment of RBCs, negates this reactivity. This study investigated the stability of the antigens on DTT-treated RBCs to determine
Wendy L. Disbro
Immunohematology, Volume 33 , ISSUE 3, 105–109
Article | 16-October-2019
to a 2–5 percent suspension in PBS.
Test DTT-treated cells with serum containing the antibody in question. Test K+ treated RBCs with anti-K.
DTT = dithiothreitol; PBS = phosphate-buffered saline; RBCs = red blood cells.
Treatment of autologous RBCs with 0.01 M DTT can resolve spontaneous agglutination due to potent IgM autoantibodies that interfere with ABO/Rh and direct antiglobulin testing.4
Monoclonal anti-CD38 (daratumumab), approved by the U.S. Food and Drug Administration for
Immunohematology, Volume 33 , ISSUE 4, 170–172